4 ms·
Proof? The point aiui is mostly arguing that the FDA errs too much on the side of caution in this area, and the trade-off would have been worth it to approve e
by drdeca 4y ago
Proof?
The point aiui is mostly arguing that the FDA errs too much on the side of caution in this area, and the trade-off would have been worth it to approve earlier. Not insinuating that like, there was some corruption (or laziness or something) that delayed it.